GlassScriptPhysician profile
William Todd Boleman
NPI 1558320119
$4,190.82
in general payments reported to CMS, 2019-2025
21 companies · $1,022 in 2025
The $1,022 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $19.92 · 2020: $111 · 2021: $313 · 2022: $746 · 2023: $1,441 · 2024: $537 · 2025: $1,022.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,999.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,710.64 | 2020-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Astrazeneca Pharmaceuticals LP | $1,138.72 | 2022-2025 | Tezspire, Fasenra, Airsupra |
| Genzyme Corporation | $363.45 | 2023-2024 | |
| Takeda Pharmaceuticals U.S.A., INC. | $221.94 | 2023-2025 | Cuvitru, Glassia, Eohilia |
| Regeneron Healthcare Solutions, INC. | $149.76 | 2023-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $101.15 | 2025 | |
| Grifols USA, LLC | $94.56 | 2023-2025 | Xembify |
| Blueprint Medicines Corporation | $66.29 | 2023-2024 | Ayvakit |
| Biocryst US Sales Co., LLC | $59.95 | 2024-2025 | Orladeyo |
| Csl Behring | $44.52 | 2024 | Hizentra |
| Ionis Pharmaceuticals, INC. | $42.35 | 2025 | Dawnzera |
| Optinose US, INC. | $27.07 | 2025 | |
| Pharming Healthcare, INC. | $26.54 | 2023 | Ruconest |
| Lilly USA, LLC | $24.65 | 2025 | Ebglyss |
| Ars Pharmaceuticals Operations, INC. | $24.29 | 2025 | Neffy |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $19.92 | 2019 | |
| Pfizer INC. | $16.78 | 2023 | |
| Alk-Abello, INC | $15.89 | 2023 | Ragwitek, Odactra, Grastek |
| Amgen INC. | $15.84 | 2023 | Tezspire |
| Merck Sharp & Dohme LLC | $14.71 | 2023 | |
| Kaleo, INC. | $11.80 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Boleman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.